Author:
Dingemanse J.,Bury M.,Joubert P.,Bock J.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Ashton H (1994) Guidelines for the rational use of benzodiazepines — when and what to use. Drugs 48:25–40
2. Balkin TJ, O'Donnell VM, Wesensten N, McCann U, Belenky G (1992) Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology 107:83–88
3. Berlin I, Warot D, Hergueta T, Molinier P, Bagot C, Puech AJ (1993) Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 13:100–106
4. Boer LC, Wientjes CJE (1988) Assessment of psychological fitness. In: Aschenbrenner H (ed) Proceedings of the workshop on psychological fitness. NATO DS/A/DR 89:107, pp 1–11
5. Dingemanse J (1995) Pharmacotherapy of insomnia: practice and prospects. Pharm World Sci: 17:67–75
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: A systematic review and meta-analysis;Journal of Clinical and Experimental Neuropsychology;2014-06-16
2. Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects;Journal of Clinical Psychopharmacology;2013-06
3. Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant;Clinical Pharmacology & Therapeutics;2010-04-07
4. Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects;Journal of Psychopharmacology;2009-07-31
5. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers;Journal of Psychopharmacology;2006-08-04